By Allison Proffitt 

 

April 26, 2013 | BioPharm Clinical has added Study Advisor forecast solution and a new user interface to its clinical trial feasibility tool. 

 

The new component is, “designed to help those individuals in clinical operations… use historical information from a predictive analysis standpoint to get a sense of what their expectations would be with regard to their upcoming study from a budgetary standpoint, the timeframe, likely length of the study, enrollment expectations, and any likely obstacles,” Sean Melville, Business Development Director at BioPharm Insight, told eCliniqua.

 

The Study Advisor component sits on BioPharm Clinical’s existing trial database, which contains more than 200,000 global studies ranging from actively recruiting studies to archived studies going back ten to fifteen years. 

 

The content of the database is gleaned from a variety of public sources. “We’ve got a team of analysts that are involved in terms of data collection, coding, and making sure that the information is all intertwined seamlessly,” Melville says.

 

BioPharm Clinical uses a three-step process to determine early study feasibility:

 

1. Analyze trial parameters; Customers input unique characteristics which define their upcoming trial, including precise indication, inclusion/exclusion criteria, geography, etc.

 

2. Generate feasibility report; Study Advisor analyzes all similar and relevant studies to forecast ideal geographies based on disease prevalence, enrollment requirements and expected timelines, likelihood of trial completion, potential obstacles, competitive activity landscape and more.

 

3. Recommend ideal sites and investigators; Study Advisor reports are integrated with BioPharm Clinical’s comprehensive database to provide detailed profiles of top sites and investigators for each geography and every indication.

 

The strength of Study Advisor within BioPharma Clinical is the comprehensiveness of the database, says Melville. Combining information on investigators and sites with trial forecasting and competitive intelligence on global clinical studies is the key differentiator, Melville says. Rather than several products each representing a piece of the puzzle, BioPharma Clinical is a “more robust” product.  

 

BioPharma Clinical is available to sponsors and CROs with a yearly subscription.